How the Framingham Risk Score works, what each risk factor contributes, statin therapy thresholds, Framingham vs ASCVD, and why Indians need a 1.4× risk correction.
Heart disease is the leading cause of death in India and worldwide. In India, cardiovascular disease accounts for over 28% of all deaths — and Indians develop heart disease at a younger age and at lower body weights than any other major ethnic group. The average age of first heart attack in India is 53 years — nearly a decade earlier than in Western countries.
The challenge of cardiovascular prevention is identifying who is at high enough risk to benefit from medication — specifically statins — before a heart attack happens. The Framingham Risk Score is the most widely used tool for this purpose. It takes seven common clinical variables and calculates your probability of having a coronary heart disease event in the next 10 years.
This guide explains exactly how it works, what the numbers mean, when to start a statin, and the critical India-specific modifications that every South Asian patient and doctor should know.
The Framingham Risk Score is derived from the Framingham Heart Study, one of the most important and long-running epidemiological studies in medical history. Begun in 1948 in Framingham, Massachusetts, it enrolled over 5,000 residents and followed them for decades — along with their children and grandchildren — to identify the factors that predict heart disease.
The study established much of what we now consider basic cardiology fact: that high blood pressure, high cholesterol, smoking, diabetes, and obesity are major cardiovascular risk factors. The risk prediction equations published by Wilson et al. in 1998 used this data to create sex-specific formulas that calculate 10-year CHD risk from seven variables.
| Variable | How Measured | Why It Matters |
|---|---|---|
| Age | Years (validated 30–79) | Age is the single strongest predictor of CHD risk — risk roughly doubles each decade |
| Sex | Male / Female | Separate equations used — men have higher baseline CHD risk; women's risk rises sharply after menopause |
| Total Cholesterol | mg/dL | Higher total cholesterol increases atherosclerosis and plaque formation |
| HDL Cholesterol | mg/dL | "Good" cholesterol — higher HDL is protective; low HDL is an independent risk factor |
| Systolic BP | mmHg | Hypertension accelerates endothelial damage and atherosclerosis |
| BP Treatment | Yes / No | Treated hypertension carries different risk than untreated at the same BP level |
| Smoking | Current smoker Yes/No | Smoking doubles CHD risk — most powerful single modifiable risk factor |
| Diabetes | Yes / No | T2DM is considered a "CHD equivalent" — dramatically increases event risk |
❤️ Use the RxMedCalc Framingham Risk Calculator — sex-specific equations with statin guidance and 10-year CHD risk output.
This is the most clinically important point for any Indian patient or doctor using the Framingham Risk Score. The Framingham equations were derived from a predominantly White American population in Massachusetts. South Asians were not included in meaningful numbers.
Multiple lines of evidence show that South Asians develop coronary artery disease at lower risk scores and at younger ages than the populations the Framingham equations were calibrated on:
Based on this evidence, the Cardiology Society of India (CSI) and multiple international guidelines recommend applying a 1.4× to 1.5× correction factor to the Framingham score for South Asian patients. A Framingham score of 12% in an Indian patient should be treated as approximately 17–18% — pushing them into a category where statin therapy is more clearly indicated.
⚠️ For Indian patients: multiply your Framingham score by 1.4. A score of 12% × 1.4 = 16.8% — intermediate-to-high risk, where a statin discussion is strongly warranted. Never use the raw score without this correction in South Asian patients.
The ACC/AHA ASCVD Pooled Cohort Equations were introduced in 2013 as an alternative to Framingham. Both tools estimate cardiovascular risk, but they have important differences:
| Feature | Framingham (1998) | ASCVD Pooled Cohort |
|---|---|---|
| Endpoint predicted | Coronary heart disease events (MI, coronary death, unstable angina) | Any atherosclerotic CV event (MI + stroke) |
| Age range validated | 30–79 years | 40–79 years |
| High risk threshold | ≥ 20% for statin | ≥ 7.5% for statin consideration |
| Populations included | White American | White and African American |
| South Asian applicability | Needs 1.4× correction | Also needs South Asian correction — tends to underestimate |
| Use in India | Widely used; familiar to most cardiologists | Growing use in tertiary centres |
Once the decision to start a statin is made, intensity of therapy is guided by the level of risk:
Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg. Target LDL reduction > 50%. For high-risk patients (≥ 20% or known CVD).
Atorvastatin 10–20 mg or Rosuvastatin 5–10 mg. Target LDL reduction 30–50%. For intermediate risk (10–20%).
Simvastatin 10–20 mg or Pravastatin 10–40 mg. LDL reduction < 30%. Rarely sufficient for primary prevention.
| Risk Category | LDL Target (mg/dL) | LDL Target (mmol/L) |
|---|---|---|
| Low risk (< 10%) | < 116 mg/dL | < 3.0 mmol/L |
| Moderate risk (10–19%) | < 100 mg/dL | < 2.6 mmol/L |
| High risk (≥ 20%) | < 70 mg/dL | < 1.8 mmol/L |
| Very high risk (known CVD, DM + risk factors) | < 55 mg/dL | < 1.4 mmol/L |
Lifestyle changes can substantially reduce cardiovascular risk — in some cases as effectively as low-to-moderate intensity statin therapy:
The Framingham Risk Score is a primary prevention tool for patients without established cardiovascular disease. It should not be used in:
This article is for educational purposes based on Framingham 1998 equations and CSI guidelines. Cardiovascular risk assessment and statin therapy decisions must be made by a qualified physician with full clinical assessment of the individual patient.
Built by an MBBS, AFIH Certified Physician in Punjab, India | RxMedCalc.com